

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

### Equality impact assessment – Guidance development

#### E-vita open plus

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

|  |
|--|
| People with connective tissue disorders such as Marfan's syndrome or Ehlers-Danlos syndrome are at an increased risk of developing a thoracic aortic aneurysm or dissection, and may require surgical intervention at a younger age. This group was highlighted in the scope for special consideration during the evaluation, although no equality issues were raised. |
|--|

|   |
|---|
| The Committee was advised that people with connective tissue disorders, for whom treatment with the E-vita open plus would be suitable, would be more likely to need further interventions in the future. This likelihood would not be determined by the choice of initial treatment. |
|---|

|   |
|---|
| The Committee concluded that the decision to use E-vita open plus or a 2-stage comparator would require careful patient selection based on the extent of their disease. |
|---|

- |  |
|--|
| 2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these? |
|--|

|  |
|--|
| No potential equality issues have been identified. |
|--|

- |   |
|---|
| 3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these? |
|---|

|  |
|--|
| No potential equality issues have been identified. |
|--|

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

The preliminary recommendations do not hinder access to the technology for any specific group.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No potential adverse impact has been identified.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No equality issues have been identified. Considerations relating to people with connective tissue disorders are included in sections 3.11, 5.24 and 6.2 of the medical technology consultation document.

**Approved by Associate Director (name):** Mark Campbell

**Date:** 08/08/2013

## Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional equality issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations were not changed following consultation. The final recommendations do not restrict access to the device by any specific group.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations were not changed following consultation. No potential adverse impact has been identified.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations were not changed following consultation and no barriers or difficulties have been identified.

5. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

No equality issues have been identified. Considerations relating to people with connective tissue disorders are included in sections 3.11, 5.24 and 6.2 of the medical technology guidance document.

**Approved by Centre or Programme Director (name):** Mirella Marlow

**Date:** [xx/xx/year]